← Back to Search

Mobile Contingency Management for Smoking Cessation (P3 Trial)

N/A
Recruiting
Led By Darla E. Kendzor, PhD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
are ≥ 18 years of age
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 26 weeks post-quit-date
Awards & highlights
No Placebo-Only Group

Summary

This trial will test an automated mobile phone-based CM approach that will allow socioeconomically disadvantaged individuals to remotely benefit from financial incentives for smoking cessation. The goal is to see if this will help people quit smoking and if it's cost effective.

Who is the study for?
This trial is for adults over 18 who smoke at least 5 cigarettes daily, want to quit within 7-14 days after joining, and earn below a certain income level. They must not use other tobacco products or have conditions that prevent using nicotine replacement therapy (NRT). A valid ID and U.S. residence proof are required.
What is being tested?
The study tests an automated mobile phone system offering financial rewards for quitting smoking against standard care with telephone counseling and NRT. Participants' success in quitting will be tracked by remote breath tests confirming no smoking.
What are the potential side effects?
While the trial itself may not directly cause side effects, nicotine replacement therapy can include symptoms like nausea, headaches, difficulty sleeping, or skin irritation where patches are applied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~26 weeks post-quit-date
This trial's timeline: 3 weeks for screening, Varies for treatment, and 26 weeks post-quit-date for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Carbon monoxide-verified smoking abstinence
Cost-effectiveness

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Contingency Management (CM)Experimental Treatment2 Interventions
CM participants will receive standard care in addition to small financial incentives for biochemically-verified abstinence.
Group II: Standard Care (SC)Active Control1 Intervention
Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,955 Previous Clinical Trials
41,111,429 Total Patients Enrolled
M.D. Anderson Cancer CenterOTHER
3,071 Previous Clinical Trials
1,802,671 Total Patients Enrolled
H. Lee Moffitt Cancer Center and Research InstituteOTHER
564 Previous Clinical Trials
143,975 Total Patients Enrolled
University of FloridaOTHER
1,409 Previous Clinical Trials
767,021 Total Patients Enrolled
University of OklahomaLead Sponsor
474 Previous Clinical Trials
93,162 Total Patients Enrolled
Darla E. Kendzor, PhDPrincipal InvestigatorUniversity of Oklahoma
3 Previous Clinical Trials
245 Total Patients Enrolled

Media Library

Smoking Cessation Research Study Groups: Standard Care (SC), Contingency Management (CM)
Smoking Cessation Clinical Trial 2023: Automated Mobile Contingency Management (CM) Highlights & Side Effects. Trial Name: NCT04881630 — N/A
~152 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top